Elanco Animal Health Incorporat ELAN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
58/100
Moderate

About Elanco Animal Health Incorporat

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and … Full ELAN analysis →

Competitive advantage assessment

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.99), demonstrating pricing resilience across cycles.
  • Operating Expense Control OpEx growth is controlled (score 0.65), demonstrating operating leverage.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.37), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
74

Where ELAN ranks in Drug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporat ranks #26 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 29%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near ELAN in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
22 Teva Pharmaceutical Industries TEVA 64/100 Moderate
23 Pacira BioSciences, Inc. PCRX 62/100 Moderate
24 Harrow, Inc. HROW 61/100 Moderate
25 Takeda Pharmaceutical Company L TAK 59/100 Moderate
26 Elanco Animal Health Incorporat ELAN 58/100 Moderate
27 Aurora Cannabis Inc. ACB 58/100 Moderate
28 Alvotech ALVO 56/100 Moderate
29 Alvotech Warrant ALVOW 56/100 Moderate
30 Supernus Pharmaceuticals, Inc. SUPN 55/100 Moderate

See every Pharma / Mature Biotech company ranked by moat score →

How ELAN scores on the Corporate Default defenses

Pricing Power

Score 74 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 69 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 61 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 49 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 47 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 49 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ELAN's moat

What is Elanco Animal Health Incorporat's moat score?

Elanco Animal Health Incorporat (ELAN) scores 58 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #26 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 29%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Pricing Power (74/100) and its weakest is Resilience (47/100).

How does Elanco Animal Health Incorporat compare with other Drug Manufacturers - Specialty & Generic companies?

Elanco Animal Health Incorporat ranks #26 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Takeda Pharmaceutical Company L (TAK) at 59 just above it and Aurora Cannabis Inc. (ACB) at 58 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Elanco Animal Health Incorporat scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Elanco Animal Health Incorporat?

The Corporate Default template measures 6 defenses, and ELAN scores: Pricing Power (74), Cost Advantage (69), Customer Stickiness (61), Capital Efficiency (49), Resilience (47), Scale & Market Position (49). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000